NASDAQ : CRBU
Caribou Biosciences, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.445 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 47.71M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 45.37M |
| Enterprise Value | -41.79M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 107.21M |
| Shares Outstanding | 107.21M |
| Shares Change (YoY) | +4.73% |
| Shares Change (QoQ) | +5.35% |
| Owned by Insiders (%) | 4.01% |
| Owned by Institutions (%) | 49.33% |
| Float | 102.91M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.52 |
| Forward PS | 1.94 |
| PB Ratio | 0.46 |
| P/TBV Ratio | 0.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.49 |
| Quick Ratio | 6.36 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -78.27% |
| Return on Assets (ROA) | -36.84% |
| Return on Invested Capital (ROIC) | -42.30% |
| Return on Capital Employed (ROCE) | -85.89% |
| Weighted Average Cost of Capital (WACC) | 10.68% |
| Revenue Per Employee | $103,454 |
| Profits Per Employee | -$1.07M |
| Employee Count | 97 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -550,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.31 |
| 52-Week Price Change | -82.14% |
| 50-Day Moving Average | 1.07 |
| 200-Day Moving Average | 1.63 |
| Relative Strength Index (RSI) | 23.12 |
| Average Volume (20 Days) | 5,917,182 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 12.55M |
| Short Previous Month | 12.91M |
| Short % of Shares Out | 11.71% |
| Short % of Float | 12.20% |
| Short Ratio (days to cover) | 2.76 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 10.04M |
| Gross Profit | -73.82M |
| Operating Income | -107.20M |
| Pretax Income | -103.95M |
| Net Income | -103.40M |
| EBITDA | -104.61M |
| EBIT | -107.20M |
| Loss Per Share | -$1.08 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 112.31M |
| Total Debt | 26.66M |
| Net Cash | 87.16M |
| Net Cash Per Share | $0.81 |
| Equity (Book Value) | 98.10M |
| Book Value Per Share | 0.93 |
| Working Capital | 98.62M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -95.78M |
| Capital Expenditures | 28,000 |
| Depreciation & Amortization | 2.59M |
| Net Borrowing | n/a |
| Free Cash Flow | -95.75M |
| FCF Per Share | -$0.89 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -1,068.22% |
| Pretax Margin | -1,035.90% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.73% |
| Shareholder Yield | -4.73% |
| Earnings Yield | -254.04% |
| FCF Yield | -211.05% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $5.75 |
| Price Target Difference | 1,258.70% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 40.39% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -5.47 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |